 Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis. Get the Inside Access Traders Are Using to Profit More and Win Bigger. 